Skip to main content
    T

    TG Therapeutics Inc (TGTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $59.83
    +1.84 (+3.18%)

    Market Cap: $8.87B

    Last updated: Nov 06, 2026 at 4:42 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    31%(12/39)
    Avg Surprise
    -1.70%

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$-0.02
    Range$-0.27 - $0.35
    4 analysts
    Revenue Consensus
    $284M
    Range$274M - $306M
    8 analysts
    Last 12 of 40 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-0.02$-0.27 - $0.35--4--
    Sep 26
    Reported Nov 2
    		$N/A$0.37$0.30 - $0.46N/ABeat4
    0
    2
    30d
    		-
    Jun 26
    Reported Aug 3
    		$0.05N/A--87.80%Miss5
    5
    0
    30d
    		-70.6%
    Mar 26
    Reported May 6
    		$0.18$0.28$0.12 - $0.46-35.71%Miss4
    1
    0
    30d
    		+500.0%
    Dec 25
    Reported Feb 26
    		$0.14N/A--60.00%Miss5
    3
    0
    30d
    		-6.7%
    Sep 25
    Reported Nov 3
    		$0.16$0.22$0.11 - $0.33-27.27%Miss6
    0
    1
    30d
    		+700.0%
    Jun 25
    Reported Aug 4
    		$0.17$0.29$0.16 - $0.61-41.38%Miss5
    1
    0
    30d
    		+325.0%
    Mar 25
    Reported May 5
    		$0.03N/A--82.35%Miss5
    0
    1
    30d
    		+142.9%
    Dec 24
    Reported Mar 3
    		$0.15$0.09$0.06 - $0.57+66.67%Beat5
    No revisions (30d)
    		+250.0%
    Sep 24
    Reported Nov 4
    		$0.02$0.03$-0.05 - $0.08-33.33%Miss8
    No revisions (30d)
    		-97.3%
    Jun 24
    Reported Aug 6
    		$0.04$-0.04$-0.09 - $-0.02+200.00%Beat7
    No revisions (30d)
    		+111.8%
    Mar 24
    Reported May 1
    		$-0.07$-0.04$-0.12 - $0.05-75.00%Miss7
    No revisions (30d)
    		+75.0%
    Dec 23
    Reported Feb 28
    		$-0.10$-0.10$-0.17 - $-0.04+0.00%Beat7
    1
    0
    30d
    		+74.4%

    Key Metrics

    Valuation
    P/E Ratio112.88EV/EBITDA59.12x
    Price/FCF487.86xFCF Yield0.20%
    Profitability
    Profit Margin55.20%Operating Margin9.02%
    ROE100.30%ROIC10.99%
    Financial Health
    Debt/Equity1.23xInterest Coverage3.18x
    Current Ratio4.27xQuick Ratio3.72x
    Trading Statistics
    Beta1.81Avg Volume1.66M
    52-Week High$63.6052-Week Low$26.76

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$58.80
    SMA 20$56.52
    SMA 50$55.80
    SMA 200$44.53
    EMA 10$58.71
    EMA 20$57.39
    EMA 50$55.63
    EMA 200$47.49

    MACD

    Line: 1.45Signal: 1.00Hist: 0.45

    ADX

    ADX: 25.1+DI: 24.4-DI: 14.2

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down8.0
    PSAR$56.84

    Bollinger Bands

    Upper Band$62.26
    Lower Band$50.77
    %B Position2032%(Upper)
    Band Width0.79

    RSI (14-Day)

    Neutral
    58.7

    Momentum Oscillators

    Stoch %K67.8
    Stoch %D71.4
    Williams %R-32.1
    ROC (10d)10.4%
    Momentum5.66
    CCI (20d)76.6
    MFI (14d)73.2

    Volatility Measures

    ATR (14d)$2.59(4.3%)
    StdDev (20d)2.87
    Hist Vol42.2%(High)

    Volume Flow

    VWAP$59.41
    OBV48.4M
    AD Line-5.4M
    CMF (20d)-0.046

    Volume Metrics

    Avg Vol (20d)1.7M
    Vol Ratio1.4x
    VWMA (20d)$57.20

    Pivot Points

    R3$64.20
    R2$62.89
    R1$60.44
    Pivot Point$59.13
    S1$56.67
    S2$55.36
    S3$52.91

    Advanced Oscillators

    TSI18.40
    Ultimate Osc45.9
    KST59.02

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$240.34M$204.92M$192.57M$161.71M$141.15M$120.86M$108.19M$83.88M$73.47M$63.47M$43.97M$165.81M
    Cost of Revenue$41.19M$33.51M$38.14M$28.09M$18.94M$15.54M$15.40M$9.34M$8.30M$5.44M$9.77M$3.51M
    Gross Profit$199.14M$171.41M$154.43M$133.62M$122.21M$105.31M$92.78M$74.54M$65.16M$58.03M$34.20M$162.31M
    Operating Expenses$177.47M$136.61M$103.94M$104.25M$87.37M$96.69M$62.84M$62.10M$56.35M$67.30M$46.69M$47.52M
    R&D$95.34M$48.40M$41.19M$40.88M$31.78M$46.36M$23.88M$20.14M$17.56M$32.72M$17.45M$14.75M
    SG&A$82.13M$88.22M$62.74M$63.37M$55.59M$50.33M$38.96M$41.97M$38.79M$34.58M$31.15M$32.77M
    Operating Income$21.67M$34.80M$50.49M$29.36M$34.84M$8.62M$29.95M$12.43M$8.82M$-9,270,000$-12,485,000$114.78M
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$16.57M$16.82M$6.53M$6.72M$6.72M$6.76M$6.93M$10.83M$3.98M$2.29M$2.43M$3.71M
    Income Before Tax$10.23M$20.36M$45.09M$25.91M$30.92M$5.47M$25.45M$4.27M$6.55M$-10,678,000$-14,026,000$113.93M
    Income Tax Expense$2.45M$586,000$22.06M$-364,986,000$2.73M$408,000$2.12M$388,000$-328,000$29,000$390,000$0
    Net Income$7.78M$19.78M$23.04M$390.89M$28.19M$5.06M$23.33M$3.88M$6.88M$-10,707,000$-14,416,000$113.93M
    EBITDA$26.89M$37.18M$51.61M$32.21M$36.72M$11.25M$31.05M$13.76M$9.44M$-9,339,000$-12,397,000$118.19M
    EBIT$26.81M$37.18M$51.63M$32.63M$37.64M$12.22M$32.38M$15.10M$10.53M$-8,390,000$-11,595,000$117.64M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TGTX

    News

    TG Therapeutics Inc (NKB2.SG) stock price, news, quote and history

    This article provides detailed financial information for TG Therapeutics Inc (NKB2.SG), including its current stock price, historical performance data...

    Yahoo Finance UK•11/3/26•Somewhat-Bullish

    TG Therapeutics, Inc. (TGTX) Seasonal returns chart

    The article displays a seasonal returns chart for TG Therapeutics, Inc. (TGTX), showing the average monthly price return from 2016 to 2026. It provides current stock information including its real-time Nasdaq price...

    Yahoo Finance UK•11/2/26•Neutral

    TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update

    TG Therapeutics, Inc. (NASDAQ: TGTX) announced it will host a conference call on Monday, November 9, 2026, at 8:30 AM ET to discuss its third-quarter 2026 financial results and provide a business outlook. Michael S....

    TG Therapeutics•11/2/26•Neutral

    TG Therapeutics stock hits 52-week high at 59.39 USD

    TG Therapeutics (TGTX) stock reached a new 52-week high of $59.39, reflecting a 70.76% increase over the past year and a nearly 95% year-to-date return. Despite a market capitalization of $8.3 billion and a P/E ratio...

    Investing.com•10/31/26•Neutral

    TG Therapeutics Stock Climbs 15% On A 6-Day Winning Streak

    Shares of TG Therapeutics (TGTX) have risen 15.1% over the last six trading sessions, adding $1.1 billion to its market value to reach $8.7 billion. This performance significantly outpaced the S&P 500...

    Trefis•10/31/26•Bullish

    TGTX Valuation and Fair Value

    P/E
    112.9x
    Forward P/E
    28.6x
    EV/EBITDA
    59.1x
    P/FCF
    487.9x
    PEG
    1.6x
    P/B
    14.0x
    See GNG's fair value

    TGTX Profitability: Margins, ROIC and FCF

    Gross margin
    82.4%
    Operating margin
    9.0%
    Net margin
    55.2%
    ROIC
    11.0%
    ROE
    100.3%
    FCF yield
    0.2%

    TGTX Competitors

    CompanyTicker
    HealthEquity IncHQY
    Bruker CorporationBRKR
    AptarGroup IncATR
    Immunitybio IncIBRX
    Spyre Therapeutics Inc.SYRE
    Twist Bioscience CorpTWST
    Krystal Biotech IncKRYS
    PACS Group, Inc.PACS

    Sector: Healthcare

    TGTX Analyst Ratings

    Consensus
    Buy
    Analysts
    8
    Strong Buy
    1
    Buy
    6
    Hold
    0
    Sell
    0
    Strong Sell
    1

    TGTX Bull Case vs Bear Case

    Bull case

    • TGTX has a 55.2% net profit margin.
    • TGTX grew quarterly revenue 70.3% year over year.
    • 87.5% of TGTX's analyst ratings are Buy or Strong Buy.

    Bear case

    • TGTX trades at 112.9x trailing earnings.
    • TGTX beat EPS estimates in 12.5% of its last 8 reported quarters.

    TGTX Earnings: Beat Rate and Next Report

    Beat rate
    1 of 8 quarters (12.5%)
    Average surprise
    -37.6%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $-0.02

    TGTX Earnings Date

    TGTX reports Nov 9, 2026, before the open. The date is confirmed.

    TGTX Earnings Call

    The latest TGTX earnings call transcript on file is labeled 2026Q2.

    Read the 2026Q2 transcript

    TGTX ETF Holders

    GNG tracks 13 ETFs that hold TGTX. The largest weights:

    1. State Street SPDR S&P Biotech ETF (XBI), 1.51% of the fund
    2. GFLW, 0.80% of the fund
    3. iShares Core S&P Small-Cap ETF (IJR), 0.46% of the fund
    4. Vanguard Morningstar Small-Cap Growth ETF (VBK), 0.22% of the fund
    5. iShares Russell 2000 ETF (IWM), 0.16% of the fund
    Open the ETF Stock Exposure tool for TGTX

    See insider activity

    Frequently Asked Questions About TGTX

    When does TGTX report earnings?

    TG Therapeutics Inc (TGTX) is confirmed to report earnings on Nov 9, 2026.

    Does TGTX pay dividends?

    TG Therapeutics Inc (TGTX) does not currently pay a regular dividend.

    What is TGTX's P/E ratio?

    TG Therapeutics Inc has a price-to-earnings (P/E) ratio of 112.88.

    What is TGTX's market cap?

    TG Therapeutics Inc (TGTX) has a market capitalization of $8.87B with a current stock price of $59.83.

    Related stocks

    Sector: Healthcare

    All stocks starting with T

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In